Lilly started phase 3 testing of LY-CoV555 to prevent COVID-19. The BLAZE-2 study will be conducted jointly with the National Institute of Allergy and Infectious Diseases. It will involve about 2400 residents and staff of nursing homes where coronavirus has been detected and there is a high risk of infection.